Overview
Employees
1-10
Investment Stage
Series A
Portfolio 31
| Date | Name | Website | Total Raised | Location |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Jan 6, 2026 | arctherapeutics.bio | arctherapeutics.bio | ||
| Nov 3, 2025 | Partillion Bioscience | partillion.com | $9.87M | United States, California, Los Angeles |
| Nov 3, 2025 | PulseSight Therapeutics | pulsesight.com | ||
| Nov 3, 2025 | AIRNA | airna.com | $275M | United States, Massachusetts, Cambridge |
| Nov 3, 2025 | HAYA Therapeutics SA | hayatx.com | $90.04M | United States, Indiana, York |
| Nov 3, 2025 | Notify Therapeutics | notifytherapeutics.com | $5.29M | Denmark, Capital Region of Denmark, Copenhagen |
| Nov 3, 2025 | AllIn Bio | allinbio.com | ||
| Oct 27, 2025 | Constructive Bio | constructive.bio | $73M | United Kingdom, England, Little Chesterford |
| Oct 27, 2025 | Lightcast | lightcast.bio | $76M | England |
Show more
Persons 3
| Date | First Name | Last Name | Title | Location | |||
| Sign up to see | Sign up to see | Sign up to see | Sign up to see | Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Alison | Palmer | Vice President of the General Partner | Sign up to see | ||||
| Gabriela | Ecco | Principal | Sign up to see |
Mentions in press and media 18
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Sep 29, 2026 | Physical AI startup SiMa.ai raises $150 million in Series C funding at $1.45 billion valuation | Physical AI startup SiMa.ai has raised $150 million in a Series C funding round, taking its total capital raised to $500 million and valuing the startup at $1.45 billion. Advertisment The round was co-led by Fidelity Management & Resear... |
| Sep 28, 2026 | SiMa.ai Closes $500 Million Series C | SAN JOSE, CA, SiMa.ai, a leader in Physical AI, announced $150 million in Series C financing, bringing the total capital raised to $500 million and valuing the company at $1.45 billion. >> Click here for more funding data on SiMa.ai ... |
| May 8, 2025 | HAYA Therapeutics: Pioneering the Future of RNA-Guided Therapies | In the world of biotechnology, innovation is the lifeblood. HAYA Therapeutics has just secured a hefty $65 million in Series A funding, a financial boost that could change the landscape of chronic and age-related disease treatment. This fun... |
| May 8, 2025 | HAYA Therapeutics banks $65 million Series A funding | HAYA Therapeutics is a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics that reprogram disease-driving cell states for rare, common, chronic and age-related diseases. The core of HAYA’s proprie... |
| Dec 14, 2023 | Vandria Announces $20.6M (CHF18M) Series A Financing Led by ND Capital to Drive CNS Clinical Program and Mitochondrial Therapeutics Platform | |
| Sep 25, 2023 | Notify Therapeutics secures €5M to develop novel hormone-free fertility treatment for women | Read this article in: Copenhagen-based Notify Therapeutics, a “first-in-class” female fertility treatment, announced that it has secured €5M in a fresh round of funding. Notify Therapeutics, an initiative stemming from Professor Karin Lykke... |
| Sep 21, 2023 | CHF 45 million Investment takes H55 next level | H55 is at the forefront of revolutionizing the aviation industry with its cutting-edge electric propulsion technologies. The company's groundbreaking solutions are designed to enhance the sustainability, efficiency, and safety of the aerosp... |
| May 5, 2021 | Cytoki Pharma cierra una ronda de €38M liderada por Lundbeckfonden Emerge junto con Ysios Capital, Seventure Partners y +ND Capital | 05/05/2021 Nota de prensa YSIOS CAPITAL INVIERTE EN CYTOKI PHARMA. − La compañía biotecnológica Cytoki Pharma (Copenhague, Dinamarca) desarrolla nuevas proteínas basadas en interleuquina 22 (IL-22) para el tratamiento de lesiones epiteli... |
| May 5, 2021 | Cytoki Pharma secures $45M Series A round lead by Lundbeckfonden Emerge together with Ysios, Seventure Partners and +ND Capital | 05/05/2021 Press release CYTOKI PHARMA RAISES $45 MILLION SERIES A FINANCING. Proceeds to support the development of its lead program (lipidated IL-22) through clinical proof of concept in Inflammatory Bowel Disease and explore expansion... |
Show more
Reviews 0
FAQ about ND CAPITAL
How many startups has ND CAPITAL invested in?
ND CAPITAL has 31 portfolio companies on Parsers VC, among them arctherapeutics.bio, Partillion Bioscience and PulseSight Therapeutics.
What has the press written about ND CAPITAL?
Parsers VC has collected 18 articles mentioning ND CAPITAL, among them “Physical AI startup SiMa.ai raises $150 million in Series C funding at $1.45 billion valuation” (Sep 29, 2026) and “SiMa.ai Closes $500 Million Series C” (Sep 28, 2026).
Is ND CAPITAL still active?
Yes, ND CAPITAL is active; its latest activity on Parsers VC dates from Sep 29, 2026.